|
|
Article: Wyeth-Ayerst Provides Background Information on Redux And Pondimin and Current Redux Clinical Studies
- Article from:
- PR Newswire
- Article date:
- March 31, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
For Immediate Release
ATLANTA, March 31 /PRNewswire/ -- Today's release of clinical data by Georgetown University and Wyeth-Ayerst Laboratories comparing echocardiograms of patients who took Redux(TM) (dexfenfluramine hydrochloride capsules) or placebo represents the first systematic step in investigating the possible relationship between Redux and Pondimin(R) (fenfluramine hydrochloride tablets) and heart valve abnormalities.
HISTORICAL BACKGROUND
On September 15, 1997, Wyeth-Ayerst Laboratories voluntarily withdrew from the market two prescription drugs for the treatment of obesity, Redux and Pondimin. This ...